ANIP

ANI Pharmaceuticals, Inc. [ANIP] Stock Forecast

Q: What is ANI Pharmaceuticals, Inc. stock symbol ?

ANI Pharmaceuticals, Inc. is a US stock, located in Baudette of Mn and trading under the symbol ANIP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ANIP Stock Summary

Earnings have grown 46.38% per last year.

Earnings are expected to rise 61.12% next year

EPS has been increasing for the past 3 quarters (Quarter statements)

Became profitable this year

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 36.9%

ANIP has less than 1 year of cash runway

Top 10 Correlated ETFs

ANIP

Top 10 Correlated Stocks

ANIP

In the News

09:26 10 Dec 2023 ANIP

ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows:

11:59 10 Dec 2023 ANIP

ANI Pharmaceuticals, Inc. (ANIP) Q3 2023 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Judy DiClemente - Insight Communications IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Participants Les Sulewski - Truist Securities Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright Operator Good day, everyone, and welcome to the ANI Pharmaceuticals, Inc. Third Quarter 2023 Earnings Results Call.

07:32 10 Dec 2023 ANIP

ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note

ANI Pharmaceuticals (ANIP) closed at $61.66 in the latest trading session, marking a -0.13% move from the prior day.

06:50 10 Dec 2023 ANIP

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open.

07:33 10 Dec 2023 ANIP

ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know

ANI Pharmaceuticals (ANIP) closed at $57.44 in the latest trading session, marking a +0.23% move from the prior day.

07:32 10 Dec 2023 ANIP

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why

The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $58.39, representing a -0.41% change from its previous close.

04:05 10 Dec 2023 ANIP

ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023

BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Global Healthcare Conference 2023 in New York City as follows:

03:47 10 Dec 2023 ANIP

Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio

ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.

10:32 10 Dec 2023 ANIP

ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

01:32 10 Dec 2023 ANIP

What Makes ANI (ANIP) a New Strong Buy Stock

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ANIP Financial details

Company Rating

Buy

Market Cap

999.68M

Income

13.38M

Revenue

449.39M

Book val./share

24.08

Cash/share

10.22

Dividend

Dividend %

Employees

600

Optionable

Shortable

Yes

Earnings

08 Nov 2023

P/E

69.06

Forward P/E

12.3

PEG

-5.92

P/S

2.22

P/B

2.03

P/C

4.79

P/FCF

18.88

Quick Ratio

2.77

Current Ratio

3.7

Debt / Equity

0.63

LT Debt / Equity

0.63

EPS (TTM)

0.56

EPS next Y

3.98

EPS next Q

0.84

EPS this Y

-12.72%

EPS next Y

610.71%

EPS next 5Y

282.14%

EPS last 5Y

NAN%

Revenue last 5Y

9.43%

Revenue Q/Q

13.11%

EPS Q/Q

53.33%

SMA20

-16.82%

SMA50

-16.32%

SMA100

-3.13%

Inst Own

56.78%

Inst Trans

0.76%

ROA

ROE

ROC

0.06%

Gross Margin

63%

Oper. Margin

10%

Profit Margin

Payout

12%

Shs Outstand

20.43M

Shs Float

16.12M

Target Price

52W Range

36.54-65.89

52W High

-24.71%

52W Low

+35.94%

RSI

33.38

Rel Volume

1.23

Avg Volume

167.31K

Volume

205.17K

Perf Week

-0.66%

Perf Month

-19.08%

Perf Quarter

-7.08%

Perf Half Y

-0.93%

Beta

0.885

Volatility

0.68%, 5.16%

Prev Close

0.43%

Price

48.94

Change

0.2%

ANIP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	17.26	17.44	17.43	17.16	19.46
Net income per share	1.33	0.51	-1.88	-3.38	-2.95
Operating cash flow per share	5.74	3.85	1.28	0.26	-1.92
Free cash flow per share	4.81	1.53	-4.43	-1.61	-2.93
Cash per share	3.68	5.26	0.66	7.96	2.97
Book value per share	16.89	17.97	16.36	28.48	20.82
Tangible book value per share	-0.68	2.43	0.3	2.92	3.61
Share holders equity per share	16.89	17.97	16.36	28.48	20.82
Interest debt per share	16.94	16.78	16.31	23.76	19.35
Market cap	525.7M	730.23M	347.43M	580.42M	654.14M
Enterprise value	665.71M	853.65M	525.26M	767.49M	892.43M
P/E ratio	33.93	119.83	-15.41	-13.62	-13.66
Price to sales ratio	2.61	3.54	1.67	2.69	2.07
POCF ratio	7.84	16	22.76	174.72	-20.96
PFCF ratio	9.36	40.38	-6.55	-28.57	-13.73
P/B Ratio	2.66	3.43	1.78	1.62	1.93
PTB ratio	2.66	3.43	1.78	1.62	1.93
EV to sales	3.3	4.13	2.52	3.55	2.82
Enterprise value over EBITDA	9.71	14.04	18.38	52.07	27.97
EV to operating cash flow	9.92	18.71	34.4	231.03	-28.6
EV to free cash flow	11.85	47.21	-9.9	-37.78	-18.73
Earnings yield	0.03	0.01	-0.06	-0.07	-0.07
Free cash flow yield	0.11	0.02	-0.15	-0.04	-0.07
Debt to equity	0.93	0.87	0.95	0.8	0.85
Debt to assets	0.43	0.41	0.4	0.37	0.38
Net debt to EBITDA	2.04	2.03	6.22	12.69	7.47
Current ratio	0.92	3.04	2.17	3.68	3.46
Interest coverage	2.4	1.26	-1.7	-2.73	-0.89
Income quality	4.33	7.49	-0.68	-0.08	0.65
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	-0.03
Sales general and administrative to revenue	0.22	0	0	0	0
Research and developement to revenue	0.08	0.1	0.08	0.05	0.07
Intangibles to total assets	0.48	0.4	0.42	0.42	0.37
Capex to operating cash flow	-0.16	-0.6	-4.48	-7.12	0.53
Capex to revenue	-0.05	-0.13	-0.33	-0.11	-0.05
Capex to depreciation	-0.32	-0.62	-1.53	-0.5	-0.28
Stock based compensation to revenue	0.03	0.04	0.06	0.05	0.05
Graham number	22.46	14.43	26.34	46.56	37.15
ROIC	0.07	0.08	-0.04	-0.04	-0.03
Return on tangible assets	0.07	0.02	-0.08	-0.09	-0.1
Graham Net	-10.4	-8.74	-12.99	-13.92	-12.09
Working capital	-12.67M	126.02M	91.76M	234.24M	244.82M
Tangible asset value	-7.92M	28.82M	3.61M	36.73M	58.68M
Net current asset value	-80.46M	-56.3M	-95.17M	-91.08M	-77.29M
Invested capital	0.93	0.87	0.95	0.8	0.85
Average receivables	61.82M	68.49M	83.96M	112.16M	146.98M
Average payables	6.26M	11.75M	12.93M	17.11M	26.14M
Average inventory	39.12M	44.33M	54.48M	71.25M	93.52M
Days sales outstanding	117.41	127.46	167.72	217.05	190.86
Days payables outstanding	44.41	84.42	47.16	83.32	77.07
Days of inventory on hand	202.45	278.36	254.63	296.37	277.08
Receivables turnover	3.11	2.86	2.18	1.68	1.91
Payables turnover	8.22	4.32	7.74	4.38	4.74
Inventory turnover	1.8	1.31	1.43	1.23	1.32
ROE	0.08	0.03	-0.12	-0.12	-0.14
Capex per share	-0.93	-2.33	-5.71	-1.88	-1.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	5.14	5.77	6.51	6.59	6.98
Net income per share	-0.53	-0.26	0.09	0.35	0.53
Operating cash flow per share	0.22	-0.27	1.31	1.17	1.7
Free cash flow per share	-0.38	-0.46	1.16	0.78	1.46
Cash per share	3.45	2.95	4.13	9.14	10.22
Book value per share	20.65	20.74	20.71	24.56	24.08
Tangible book value per share	2.71	3.59	4.42	9.95	10.94
Share holders equity per share	20.65	20.74	20.71	24.56	24.08
Interest debt per share	18.03	18.01	17.94	16.58	15.48
Market cap	523.98M	656.75M	651.09M	952.15M	1.1B
Enterprise value	754.43M	895.05M	869.64M	1.08B	1.19B
P/E ratio	-15.23	-38.7	113.12	38.12	27.57
Price to sales ratio	6.25	6.97	6.1	8.17	8.32
POCF ratio	144.63	-149.26	30.39	46.16	34.08
PFCF ratio	-84.64	-87.08	34.14	69	39.7
P/B Ratio	1.56	1.94	1.92	2.19	2.41
PTB ratio	1.56	1.94	1.92	2.19	2.41
EV to sales	9	9.5	8.14	9.24	9.02
Enterprise value over EBITDA	52.36	46.01	32.63	38.34	38.91
EV to operating cash flow	208.23	-203.42	40.59	52.19	36.97
EV to free cash flow	-121.86	-118.67	45.6	78.01	43.06
Earnings yield	-0.02	-0.01	0	0.01	0.01
Free cash flow yield	-0.01	-0.01	0.03	0.01	0.03
Debt to equity	0.85	0.85	0.84	0.66	0.63
Debt to assets	0.39	0.38	0.37	0.33	0.32
Net debt to EBITDA	15.99	12.25	8.2	4.43	3.04
Current ratio	3.79	3.46	2.9	3.74	3.7
Interest coverage	-0.13	0.66	1.29	1.75	2.81
Income quality	-0.42	1.04	14.89	3.3	3.24
Dividend Yield	0	0	0	0	0
Payout ratio	-0.05	-0.1	0.28	0.07	0.04
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.09	0.06	0.06	0.06	0.08
Intangibles to total assets	0.4	0.37	0.35	0.3	0.28
Capex to operating cash flow	-2.71	0.71	-0.11	-0.33	-0.14
Capex to revenue	-0.12	-0.03	-0.02	-0.06	-0.03
Capex to depreciation	-0.64	-0.2	-0.16	-0.46	-0.3
Stock based compensation to revenue	0.05	0.04	0.04	0.05	0.04
Graham number	15.66	11.01	6.4	13.97	16.89
ROIC	0	0.01	0.01	0.02	0.02
Return on tangible assets	-0.02	-0.01	0	0.01	0.02
Graham Net	-11.83	-12.04	-10.68	-4.6	-2.9
Working capital	227.75M	244.82M	238.93M	336.45M	362.87M
Tangible asset value	44.22M	58.68M	72.47M	175.95M	206.66M
Net current asset value	-93.06M	-77.29M	-60.99M	34.44M	62.02M
Invested capital	0.85	0.85	0.84	0.66	0.63
Average receivables	145.42M	152.94M	170.08M	173.82M	175.88M
Average payables	23.32M	24.15M	31M	30.6M	31.29M
Average inventory	94.22M	100.62M	104.5M	103.99M	105.46M
Days sales outstanding	150.79	158.01	147.25	133.54	122.1
Days payables outstanding	51.96	72.61	78.02	60.67	63.76
Days of inventory on hand	262.37	261.02	247.4	222.05	199.44
Receivables turnover	0.6	0.57	0.61	0.67	0.74
Payables turnover	1.73	1.24	1.15	1.48	1.41
Inventory turnover	0.34	0.34	0.36	0.41	0.45
ROE	-0.03	-0.01	0	0.01	0.02
Capex per share	-0.6	-0.19	-0.14	-0.39	-0.24

ANIP Frequently Asked Questions

What is ANI Pharmaceuticals, Inc. stock symbol ?

ANI Pharmaceuticals, Inc. is a US stock , located in Baudette of Mn and trading under the symbol ANIP

Is ANI Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $48. The lowest prediction is $48 and the highest is $48

What is ANIP stock prediction ?

What is ANI Pharmaceuticals, Inc. stock quote today ?

ANI Pharmaceuticals, Inc. stock price is $48.94 today.

Is ANI Pharmaceuticals, Inc. stock public?

Yes, ANI Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 167.31K
Market Capitalization 999.68M
Employee 600
CEO Mr. Nikhil Lalwani
Headquarters Baudette,MN,US
IPO Date 2000-05-05
Website https://www.anipharmaceuticals.com

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.